|
1
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Le DT, Uram JN, Wang H, Bartlett BR,
Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et
al: PD-1 blockade in tumors with mismatch-repair deficiency. N Engl
J Med. 372:2509–2520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Herbst RS, Soria JC, Kowanetz M, Fine GD,
Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger
SN, et al: Predictive correlates of response to the anti-PD-L1
antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lin WF, Lu JY, Cheng BB and Ling CQ:
Progress in research on the effects of traditional Chinese medicine
on the tumor microenvironment. J Integr Med. 15:282–287. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Taube JM, Anders RA, Young GD, Xu H,
Sharma R, McMiller TL, Chen S, Klein AP, Pardoll DM, Topalian SL
and Chen L: Colocalization of inflammatory response with B7-h1
expression in human melanocytic lesions supports an adaptive
resistance mechanism of immune escape. Sci Transl Med.
4:127ra372012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Taube JM, Klein A, Brahmer JR, Xu H, Pan
X, Kim JH, Chen L, Pardoll DM, Topalian SL and Anders RA:
Association of PD-1, PD-1 ligands, and other features of the tumor
immune microenvironment with response to anti-PD-1 therapy. Clin
Cancer Res. 20:5064–5074. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kalbasi A, June CH, Haas N and Vapiwala N:
Radiation and immunotherapy: A synergistic combination. J Clin
Invest. 123:2756–2763. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang RR, Jalil J, Economou JS,
Chmielowski B, Koya RC, Mok S, Sazegar H, Seja E, Villanueva A,
Gomez-Navarro J, et al: CTLA4 blockade induces frequent tumor
infiltration by activated lymphocytes regardless of clinical
responses in humans. Clin Cancer Res. 17:4101–4109. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wolchok JD, Kluger H, Callahan MK, Postow
MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K,
et al: Nivolumab plus ipilimumab in advanced melanoma. N Engl J
Med. 369:122–133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Teng MW, Ngiow SF, Ribas A and Smyth MJ:
Classifying cancers based on t-cell infiltration and PD-L1. Cancer
Res. 75:2139–2145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Klintrup K, Mäkinen JM, Kauppila S, Väre
PO, Melkko J, Tuominen H, Tuppurainen K, Mäkelä J, Karttunen TJ and
Mäkinen MJ: Inflammation and prognosis in colorectal cancer. Eur J
Cancer. 41:2645–2654. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shen SJ, Zhang YH, Gu XX, Jiang SJ and Xu
LJ: Yangfei Kongliu Formula, a compound Chinese herbal medicine,
combined with cisplatin, inhibits growth of lung cancer cells
through transforming growth factor-β1 signaling pathway. J Integr
Med. 15:242–251. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Droeser RA, Hirt C, Viehl CT, Frey DM,
Nebiker C, Huber X, Zlobec I, Eppenberger-Castori S, Tzankov A,
Rosso R, et al: Clinical impact of programmed cell death ligand 1
expression in colorectal cancer. Eur J Cancer. 49:2233–2242. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang Y, Sun Z, Mao X, Wu H, Luo F, Wu X,
Zhou L, Qin J, Zhao L and Bai C: Impact of mismatch-repair
deficiency on the colorectal cancer immune microenvironment.
Oncotarget. 8:85526–85536. 2017.PubMed/NCBI
|
|
16
|
Park JH, Powell AG, Roxburgh CS, Horgan
PG, McMillan DC and Edwards J: Mismatch repair status in patients
with primary operable colorectal cancer: Associations with the
local and systemic tumour environment. Br J Cancer. 114:562–570.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Smyrk TC, Watson P, Kaul K and Lynch HT:
Tumor-infiltrating lymphocytes are a marker for microsatellite
instability in colorectal carcinoma. Cancer. 91:2417–2422. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Inaguma S, Lasota J, Felisiak-Golabek A,
Kowalik A, Wang Z, Zieba S, Kalisz J, Ikeda H and Miettinen M:
Histopathological and genotypic characterization of metastatic
colorectal carcinoma with PD-L1 (CD274)-expression: Possible roles
of tumour micro environmental factors for CD274 expression. J
Pathol Clin Res. 3:268–278. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Rosenbaum MW, Bledsoe JR, Morales-Oyarvide
V, Huynh TG and Mino-Kenudson M: PD-L1 expression in colorectal
cancer is associated with microsatellite instability, BRAF
mutation, medullary morphology and cytotoxic tumor-infiltrating
lymphocytes. Mod Pathol. 29:1104–1112. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen DS, Irving BA and Hodi FS: Molecular
pathways: Next-generation immunotherapy-inhibiting programmed
death-ligand 1 and programmed death-1. Clin Cancer Res.
18:6580–6587. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Woerner SM, Gebert J, Yuan YP, Sutter C,
Ridder R, Bork P and von Knebel Doeberitz M: Systematic
identification of genes with coding microsatellites mutated in DNA
mismatch repair-deficient cancer cells. Int J Cancer. 93:12–19.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Angelova M, Charoentong P, Hackl H,
Fischer ML, Snajder R, Krogsdam AM, Waldner MJ, Bindea G, Mlecnik
B, Galon J and Trajanoski Z: Characterization of the
immunophenotypes and antigenomes of colorectal cancers reveals
distinct tumor escape mechanisms and novel targets for
immunotherapy. Genome Biol. 16:642015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dong H, Zhu G, Tamada K and Chen L: B7-H1,
a third member of the B7 family, co-stimulates T-cell proliferation
and interleukin-10 secretion. Nat Med. 5:1365–1369. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Freeman GJ, Long AJ, Iwai Y, Bourque K,
Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne
MC, et al: Engagement of the PD-1 immunoinhibitory receptor by a
novel B7 family member leads to negative regulation of lymphocyte
activation. J Exp Med. 192:1027–1034. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tseng SY, Otsuji M, Gorski K, Huang X,
Slansky JE, Pai SI, Shalabi A, Shin T, Pardoll DM and Tsuchiya H:
B7-DC, a new dendritic cell molecule with potent costimulatory
properties for T cells. J Exp Med. 193:839–846. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sznol M and Chen L: Antagonist antibodies
to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human
cancer. Clin Cancer Res. 19:1021–1034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Aboudaram A, Modesto A, Chaltiel L,
Gomez-Roca C, Boulinguez S, Sibaud V, Delord JP, Chira C, Delannes
M, Moyal E and Meyer N: Concurrent radiotherapy for patients with
metastatic melanoma and receiving anti-programmed-death 1 therapy:
A safe and effective combination. Melanoma Res. 27:485–491. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Karaca B, Yayla G, Erdem M and Gürler T:
Electrochemotherapy with anti-PD-1 treatment induced durable
complete response in heavily pretreated metastatic melanoma
patient. Anticancer Drugs. Dec 21–2017.(Epub ahead of print). doi:
10.1097/CAD.0000000000000580. View Article : Google Scholar
|
